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The protein kinase casein kinase 2 (CK2) is a pleiotropic
and constitutively active kinase that plays crucial roles in cel-
lular proliferation and survival. Overexpression of CK2, par-
ticularly the  catalytic subunit (CK2, CSNK2A1), has been
implicated in a wide variety of cancers and is associated with
poorer survival and resistance to both conventional and tar-
geted anticancer therapies. Here, we found that CK2 pro-
tein is elevated in melanoma cell lines compared with normal
human melanocytes. We then tested the involvement of
CK2 in drug resistance to Food and Drug Administration-
approved single agent targeted therapies for melanoma. In
BRAF mutant melanoma cells, ectopic CK2 decreased sen-
sitivity to vemurafenib (BRAF inhibitor), dabrafenib (BRAF
inhibitor), and trametinib (MEK inhibitor) by a mechanism
distinct from that of mutant NRAS. Conversely, knockdown
of CK2 sensitized cells to inhibitor treatment. CK2-medi-
ated RAF-MEK kinase inhibitor resistance was tightly linked
to its maintenance of ERK phosphorylation. We found that
CK2 post-translationally regulates the ERK-specific phos-
phatase dual specificity phosphatase 6 (DUSP6) in a kinase
dependent-manner, decreasing its abundance. However, we
unexpectedly showed, by using a kinase-inactive mutant of
CK2, that RAF-MEK inhibitor resistance did not rely on
CK2 kinase catalytic function, and both wild-type and
kinase-inactive CK2 maintained ERK phosphorylation
upon inhibition of BRAF or MEK. That both wild-type and
kinase-inactive CK2 bound equally well to the RAF-MEK-
ERK scaffold kinase suppressor of Ras 1 (KSR1) suggested
that CK2 increases KSR facilitation of ERK phosphor-
ylation. Accordingly, CK2 did not cause resistance to di-
rect inhibition of ERK by the ERK1/2-selective inhibitor
SCH772984. Our findings support a kinase-independent
scaffolding function of CK2 that promotes resistance to
RAF- and MEK-targeted therapies.
The protein kinase casein kinase 2 or II (CK2)2 is a highly
conserved, ubiquitously expressed, pleiotropic, and constitu-
tively active serine/threonine kinase that has crucial roles in
cell survival, proliferation, and differentiation (2–4). The CK2
holoenzyme consists of two regulatory () and two catalytic (
or ) subunits, the latter of which can also function indepen-
dently of the tetramer (5). Although CK2 itself does not appear
to be a proto-oncogene, its up-regulation has been shown to
promote growth and prevent apoptosis, both of which promote
cancer (4). Indeed, overexpression of CK2 at the transcript
and/or protein level has been observed in many cancers (6),
includingmultiplemyeloma (7), chronic lymphocytic leukemia
(8), breast cancer (9), colorectal cancer (10), liver cancer (11),
etc. and is correlated with poorer patient survival (6, 10, 12).
Similarly, CK2 exhibited 2.5-fold higher catalytic activity in
metastatic melanoma than in dermal nevi (13).
In addition to its roles in tumor growth and progression, CK2
also promotes drug resistance to both conventional and tar-
geted therapeutics. For example, pharmacological inhibition of
CK2 kinase activity revertedmultidrug resistance of a humanT
lymphoblastoid cell line (14) at least in part by down-regulating
P-glycoprotein activity. In addition, siRNA-mediated knock-
down of CK2 catalytic subunits enhanced chemosensitivity to
gemcitabine in human pancreatic cancer cells (15). In cells
depleted of CK2, gemcitabine induced MKK4/JNK signaling,
resulting in cell death (15). Furthermore, CK2 displayed ele-
vated protein expression and activity in chronic myeloid leuke-
mia cells that are resistant to the small molecule kinase inhibi-
tor imatinib (16). Either reduction of CK2 expression or
pharmacological inhibition of CK2 kinase activity restored
imatinib sensitivity, possibly through suppressing Akt activity
(16). However, the role of CK2 in drug resistance, particularly
to targeted therapeutics, has remained underexplored.
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Inhibitors of BRAF and MEK, members of the RAF-MEK-
ERKkinase cascade, have achieved remarkable overall response
rates in advanced melanomas harboring BRAF Val-600 muta-
tions, but a significant proportion of patients is intrinsically
resistant to such therapies, and those who respond almost
inevitably develop resistance over a matter of months (17).
Considerable efforts have been invested in identifying resis-
tance mechanisms of BRAFmutant melanomas to BRAF inhi-
bition, and somehave demonstrated clinical relevance (18–21).
In a recent whole-kinome siRNA screen for kinases that could
induce resistance to ERK kinase inhibitors in pancreatic ductal
adenocarcinoma cells, we identified CK2 as a synthetic lethal
partner of ERK inhibition (22). We postulated that kinase
inhibitor resistance mechanisms can be shared by diseases that
show hyperactivity of the same pathway. Given that the RAF-
MEK-ERK pathway is strongly activated in both pancreatic
cancer and melanoma, we sought to determine whether CK2
also plays a role in resistance to inhibition of this pathway in
melanoma.
In the present study, we found that CK2 overexpression
was sufficient to drive resistance to both BRAF andMEK inhib-
itors in BRAFmutant melanoma cells. Conversely, depletion of
CK2 increased sensitivity to the BRAF inhibitor vemurafenib.
Consistent with these results, CK2 sustained ERK phosphor-
ylation under conditions of pathway inhibition. Although we
found that CK2 negatively regulated expression of the ERK-
specific phosphatase dual specificity phosphatase 6 (DUSP6) in
a kinase-dependent manner, the maintenance of ERK phos-
phorylation was not due to these decreased levels of DUSP6.
Instead, we found that CK2-mediated maintenance of ERK
phosphorylation and drug resistance were kinase-independent.
The ability of both wild-type and kinase-inactive CK2 to bind
to the key RAF-MEK-ERKpathway scaffold protein kinase sup-
pressor of Ras 1 (KSR1), which is required for optimal ERK
phosphorylation and activation, supports a kinase-indepen-
dent scaffolding role for CK2 in facilitating optimal ERK sig-
naling under conditions of pathway inhibition. That CK2
overexpression did not cause resistance to a direct ERK inhib-
itor is further evidence that ERK inhibitionmayovercome resis-
tance mechanisms that shorten the effectiveness of blocking
upstream kinases in the RAF-MEK-ERK pathway.
Results
CK2Expression IsUp-regulated in a Subset ofMelanomas—
To examine the expression of CK2 in melanoma, we first sur-
veyed theCancerGenomeAtlas skin cutaneousmelanomadata
set for CK2 mRNA expression through cBioPortal (40). We
found that the CK2 transcript is up-regulated in a subset of
those tumors (15% of 278 samples) and that 90% of that subset
also harbor mutations in BRAF, NRAS, and/or NF1 that lead
to hyperactivation of ERK. Next, we measured CK2 protein
expression in a panel of neonatal human epidermal melano-
cytes, lightly pigmented, moderately pigmented, and darkly
pigmented donors andmelanoma cell lines (five BRAFmutants
(A375, SK-MEL-28,A2058, RPMI-7951, andMalme-3) andone
NRAS mutant (SBC12A)) (Fig. 1A). Melanoma cell lines had
higher levels of CK2 protein expression compared with mela-
nocytes (Fig. 1B; p 0.013). In contrast, basal phosphorylated
ERK (pERK) levelswere quite variable among the lines andwere
not predicted either by malignancy state (p  0.5384) or by
CK2 levels (R2  0.06130) (Fig. 1A), consistent with our pre-
vious findings (see Fig. 1 in Shields et al. (23)).
CK2 Promotes Resistance to Inhibitors of BRAF andMEK in
BRAF Mutant Melanoma Cells—We recently used a whole-
kinome siRNA screen to search formechanisms of resistance to
ERK inhibition in pancreatic ductal adenocarcinoma cell, and
found that CK2 was one of the hits identified (22). To test
whether CK2 promotes resistance to approved single agent
therapies targeting the RAF-MEK-ERK pathway in melanoma
cells with hyperactivation of this pathway, we first stably
expressed FLAG-tagged wild-type CK2 in A375 melanoma
cells (Fig. 2A). These cells possess a homozygous BRAF(V600E)
mutation and are sensitive to both BRAFi and MEKi. We then
assessed sensitivity to growth inhibition by multiple inhibitors
of the pathway, including mutant BRAF-selective inhibitors
vemurafenib and dabrafenib and MEK1/2-selective inhibitor
trametinib. Oncogenically activated (mutant) NRAS has been
identified in patients with BRAF mutant melanomas as one
mechanism of resistance to BRAF but not MEK inhibition
FIGURE 1. CK2 protein expression is elevated in melanoma cell lines
comparedwithmelanocytes. A, cell lysates from a panel consisting of three
types of neonatal epidermal melanocytes from lightly pigmented (LP), mod-
erately pigmented (MP), anddarkly pigmented (DP) donors and fiveBRAFand
oneNRASmutantmelanomacell lineswereprobed forCK2proteinbyWest-
ern blotting with anti-CK2 antibody. -Tubulin was used as a loading con-
trol. Normalized expression of CK2/-tubulin is shown. Phosphorylation of
ERKwasmeasured and normalized to total ERK (tERK). B, statistical analysis of
normalized CK2 expression (*, p 0.013). Error bars represent S.E.
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(24). Therefore, we stably expressed FLAG-tagged mutant
NRAS(Q61K) (Fig. 2A) as a positive control. Expression of
CK2 or NRAS(Q61K) led to an 1.62-fold increase in basal
ERK phosphorylation (Fig. 2B). But, as expected, mutant NRAS
promoted resistance to both BRAF inhibitors vemurafenib and
dabrafenib as evidenced by increased values for 50% growth
inhibition (GI50) of 11.4- and 2.97-fold, respectively, compared
with the GFP negative control (Fig. 2D). In contrast, mutant
NRAS did not increase the GI50 (1.1-fold change) for theMEKi
trametinib, consistent with findings that BRAF mutant mela-
nomaswith secondaryNRASmutations still remain sensitive to
MEK inhibition (24). Notably, expression of CK2 increased
the GI50 for vemurafenib, dabrafenib, and trametinib by 4.13-,
3.52-, and 2.63-fold, respectively, indicating reduced sensitivity
to all three inhibitors (Fig. 2C). A summary of all GI50 values are
provided in a table in Fig. 2C, lower panel. Expression of CK2
also produced resistance to vemurafenib in another BRAF
mutant melanoma cell line, SK-MEL-28 (data not shown). To
further evaluate the effect of CK2 expression on responses to
the above mentioned inhibitors, we performed clonogenic cell
survival assays, which assess the ability of individual cells to
form colonies, a property that differs between tumor cells and
their normal counterparts and that is distinct from the prolif-
eration of an overall cell population as measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
Consistent with the increased GI50 values, CK2 enhanced the
clonogenic survival ofA375 cells asmeasured by percent colony
numbers in the presence of each inhibitor compared with
DMSO vehicle control (Fig. 2D). In contrast to CK2,
NRAS(Q61K) significantly enhanced clonogenic survival only
in response to vemurafenib. The modest enhancement in
clonogenic survival in response to dabrafenib did not reach sta-
tistical significance. Together, these results indicate that CK2
overexpression but not NRAS mutation is sufficient to induce
resistance to both BRAF and MEK inhibition, which implies a
CK2-mediated resistance mechanism distinct from that
mediated by mutant NRAS.
CK2 Depletion Sensitizes Melanoma Cells to BRAF
Inhibition—Given that CK2 overexpression was sufficient to
drive resistance, we asked whether, conversely, depletion of
CK2 would enhance sensitivity to pathway inhibition. We
used a set of five shRNAs (1–5) to knock down CK2 in A375
cells. Consistent with themild increase in basal ERK phosphor-
ylation when CK2 was overexpressed (Fig. 2B), we found that
ERK phosphorylation was mildly impaired upon CK2 knock-
down (data not shown). Complete knockdown of CK2 was
incompatible with cell survival (data not shown). Therefore,
to obtain cells for subsequent experimentation, we utilized
shRNAs 4 and 5, which yielded 60% knockdown and suffi-
cient viability (Fig. 3A). Even this incomplete depletion ofCK2
expression resulted in decreased GI50 for vemurafenib (55 and
65% decrease for shRNAs 4 and 5, respectively; Fig. 3B). This
result indicates that CK2 is necessary for resistance to BRAF
inhibition.
CK2 Sustains ERK Phosphorylation under Conditions of
RAF-MEK-ERK Pathway Inhibition—Previous studies have
identified multiple mechanisms of resistance to BRAF inhibi-
tion, the majority of which are characterized by ERK reactiva-
tion (25). Given that CK2 and mutant NRAS both promote
BRAFi resistance, we hypothesized that they are both capable of
facilitating ERK reactivation following inhibition of BRAF
and/or MEK. As anticipated, mutant NRAS induced strong
ERK reactivation upon inhibition of BRAF with either vemu-
rafenib or dabrafenib (Fig. 4, A and B). CK2 also facilitated
ERK rebound although not as strongly as NRAS(Q61K). Con-
sistent with their trametinib resistance profiles, NRAS(Q61K)
failed to reactivate ERK in the presence of trametinib, whereas
CK2 did sustain ERK phosphorylation (Fig. 4C). The mainte-
nance of ERK phosphorylation byCK2 suggested eithermain-
FIGURE 2. Ectopic CK2promotes resistance to inhibitors of BRAF andMEK. A, A375 cells were stably infectedwith lentiviral vectors to ectopically express
GFP negative control or FLAG-tagged CK2 or NRAS(Q61K), and cell lysates were subjected to Western blotting using anti-FLAG, anti-GFP, and anti-CK2
antibodies.-Actin served as a loading control. B, expression of CK2orNRAS(Q61K) increases the basal level of ERKphosphorylation in A375 cells by 1.62-fold
as determined by Western blotting using anti-phospho-ERK(Thr-202/Tyr-204) antibody and normalized to total ERK (t-ERK) (n 5). C, CK2 increases GI50 for
BRAFi vemurafenib, BRAFi dabrafenib, andMEKi trametinib. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide assayswere performedafter 72 hof
treatment with nine different doses of inhibitors, and dose-response curves were generated by GraphPad Prism v5.0c. Results are presented as means S.E.
(n 6). A summary of all GI50 values is shown in the table below.D, CK2 enhances clonogenic survival of inhibitor-treated A375 cells. Cells as in the previous
panels were grown for 2 weeks on plastic as single colonies in the presence of vemurafenib (1 M), dabrafenib (100 nM), trametinib (1 nM), or DMSO vehicle
control. Shown are the percentage of colonies formed in the presence of each inhibitor relative to the vehicle control. Results are presented asmeans S.E. **,
p 0.01; *, p 0.05 (n 3). Crystal violet-stained images of colonies are shown in the lower panel. Error bars represent S.E.
FIGURE 3. Suppression of endogenous CK2 increases sensitivity to the
BRAF inhibitor vemurafenib. A, endogenous CK2was suppressed in A375
cells by using five different shRNA sequences, and the degree of knockdown
was assessed byWestern blotting using anti-CK2 antibody. -Actin served as
a loading control. The percentage of knockdown achieved by each shRNA
directed against CK2, normalized to the non-targeting (NT) shRNA, is indi-
catedbeloweach lane. tERK, total ERK.B, knockdownof60%ofendogenous
CK2 (A) is sufficient to decrease the GI50 for vemurafenib. GI50 curves for
A375 cells infectedwith either non-targeting shRNAor shRNA4 (black dashed
line) or shRNA 5 (black dotted line) are shown. Results are presented as
means S.E. (n 3). Error bars represent S.E.
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tained upstream activation or suppressed deactivation mecha-
nisms. MEK is the only known direct activator of ERK (26), and
phosphorylation of MEK at Ser-217 and Ser-221 is indicative
of MEK activation. DUSP6/mitogen-activated kinase kinase
phosphatase 3 is a key ERK-specific phosphatase that reverses
MEKphosphorylation at the TEYmotif of ERK (27). Therefore,
we assessed the status of both MEK activation and DUSP6
expressionbyWesternblotting.We found thatMEKphosphor-
ylation did not change in parallel with ERK phosphorylation,
indicating that it is not the basis for maintained ERK activity
(Fig. 4C). Intriguingly, DUSP6 expression was also strongly
reduced in CK2-overexpressing cells even without inhibitor
treatment (Fig. 4C). Based on this finding, we initially hypoth-
esized that down-regulation of DUSP6 contributed to the sus-
tained ERK phosphorylation. However, we first needed to con-
firm whether CK2 truly regulates DUSP6 expression.
CK2Regulates DUSP6 Protein Levels in a Kinase-dependent
Manner—CK2 has been reported to directly phosphorylate
DUSP6 at multiple sites in vitro, the consequences of which are
largely unknown (28). To control for CK2 kinase activity, we
generated a kinase-inactivemutant of CK2 (29) andmeasured
DUSP6 protein levels upon ectopic expression of either kinase-
inactive (K68M) or wild-type (WT) CK2. As expected,
CK2(WT) was constitutively active, and cells overexpressing
this form of CK2 exhibited elevated basal phosphorylation of
EEF1D (Fig. 5A), a validated marker of CK2 activity (30). In
contrast, cells expressing kinase-inactive CK2(K68M) exhib-
ited mildly reduced levels of EEF1D phosphorylation (Fig. 5A),
suggesting a weak dominant-negative effect. Interestingly,
CK2(WT) drastically reduced DUSP6 abundance, whereas
K68M did not have an effect (Fig. 5B), indicating that the
decrease in DUSP6 protein is likely due to CK2-mediated
phosphorylation. Conversely, shRNA-mediated knockdown of
endogenous CK2 enhanced DUSP6 protein levels (Fig. 5C).
To determinewhether the reduction inDUSP6was the result of
accelerated degradation or suppressed transcription, we first
used MG132 to block proteasome-mediated protein degrada-
tion. Six hours after MG132 treatment, DUSP6 abundance was
fully rescued (Fig. 5D). We also examinedDUSP6mRNA levels
by quantitative PCR and found that they did not change upon
CK2 expression (Fig. 5E). These results indicate that CK2
kinase activity regulates DUSP6 abundance by facilitating its
proteasomal degradation.
CK2-mediated Maintenance of ERK Phosphorylation and
Pathway Inhibitor Resistance Does Not Require Its Kinase
Function—Given that CK2 kinase activity was essential to the
decrease in DUSP6 expression (Fig. 5B), we hypothesized that
kinase-inactive CK2would not be able tomaintain ERK phos-
phorylation when the pathway was inhibited. Unexpectedly, in
the presence of both BRAFis, ERK phosphorylation was
sustained to a similar degree in the presence of either
CK2(K68M)orCK2(WT)(Fig.6A), suggestingakinase-inde-
pendent contribution of CK2 to pERK. However, in the pres-
ence of MEKi, CK2(K68M) exhibited a lower level of pERK
compared with CK2(WT). This potentially indicates a differ-
ential contribution of the kinase activity of CK2 to maintain-
ing pERK, depending onwhich node of the pathway is inhibited
(Fig. 6A). We therefore anticipated that kinase-inactive CK2
would also promote resistance in a similar fashion. Consistent
with this, we found that CK2(K68M) promoted resistance to
vemurafenib, dabrafenib, and trametinib to the same extent
as CK2 wild type as indicated by their respective GI50 val-
ues (Fig. 6B), indicating that CK2-mediated BRAFi and
MEKi resistance does not depend on its catalytic kinase
activity. Instead, our findings indicate that the ability of
CK2 to maintain ERK phosphorylation when the pathway is
inhibited and to promote resistance to BRAF and MEK
inhibitors is more likely due to a protein binding or scaffold-
ing function of CK2. Clearly, CK2(K68M), although cata-
lytically inactive and incapable of degrading DUSP6, main-
tained ERK phosphorylation and inhibitor resistance.
Therefore, DUSP6 regulation by CK2 does not contribute
to CK2-mediated resistance and maintenance of pERK or
cell viability upon inhibitor treatment.
CK2(WT) and CK2(K68M) Bind Equally Well to the RAF-
MEK-ERK Scaffold Protein KSR1—Our previous work (31)
uncovered an essential role of CK2 in maximally facilitating
FIGURE 4.Overexpressed CK2 accelerates ERK rebound or sustains ERK
phosphorylation in response to RAF-MEK-ERK pathway inhibition. pERK
was evaluated by Western blotting analysis of lysates from A375 cells ectop-
ically expressing GFP, CK2, or NRAS(Q61K) treated for 24, 48, or 72h with
vemurafenib (Vem) (BRAFi; 1 M) (A), dabrafenib (Dab) (BRAFi; 100 nM) (B), or
trametinib (Tram) (MEKi; 1 nM) (C). Total ERK1/2 (tERK) served as a loading
control. MEKi (trametinib)-treated cell lysates were additionally immuno-
blotted for phospho-MEK1/2 (pMEK) and for the ERK-specific phosphatase
DUSP6. Densitometry values for pERK/total ERK are shown for each panel.
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FIGURE 5. CK2 decreases protein stability of the ERK phosphatase DUSP6 in a kinase-dependent manner. A, phosphorylation of the CK2 substrate
EEF1DuponexpressionofWTor kinase-inactive (K68M)CK2wasdetectedbyWesternblottingwithaphospho-EEF1Dantibody. Levels of endogenousDUSP6
protein were determined by Western blotting of lysates from A375 cells ectopically expressing CK2(WT) or CK2(K68M) (B) or from A375 cells depleted of
endogenous CK2 by two different shRNAs (same lysates as shown in Fig. 3A) (C). D, to determine whether CK2 regulates DUSP6 protein stability, the same
cells as in Bwere immunoblotted for DUSP6 protein after treatment for 6 hwith either the proteasome inhibitor MG132 (10M) or DMSO vehicle control. E, to
determine whether CK2 also regulates DUSP6 at the transcriptional level, quantitative RT-PCR analysis of DUSP6 mRNA levels was done on cells expressing
CK2(WT) or kinase-inactive CK2(K68M). Results are presented as means S.E. (n 3). Error bars represent S.E. n.s., not significant.
FIGURE 6. CK2-mediated maintenance of ERK phosphorylation upon pathway inhibition and resistance to BRAFi/MEKi are both kinase-indepen-
dent. A, A375 cells ectopically expressing GFP, CK2(K68M), or CK2(WT) were treated with BRAFi and MEKi as in Fig. 4, then lysed, and immunoblotted for
pERK and total DUSP6. Total ERK (tERK) served as loading control. B, cells were treated as in A, and GI50 curves were generated after 72 h. A summary of GI50
values is shown in a table below. Results are presented as means S.E. (n 4). Error bars represent S.E. Vem, vemurafenib;Dab, dabrafenib; Tram, trametinib.
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RAF-MEK-ERK pathway activation through its direct binding
toKSR1within theKSR1 scaffolding complex that also includes
RAF, MEK, and ERK. CK2 association with KSR enhances
RAF phosphorylation of MEK. Given our finding here that
kinase-inactive CK2 maintains ERK phosphorylation and
resistance to pathway inhibitors to the same extent as its wild-
type counterpart, we speculated that it too retains binding to
KSR1. Accordingly, when we immunoprecipitated endogenous
KSR1 fromA375 cells, we detected considerable levels of ectop-
ically expressed CK2(WT) and CK2(K68M) but not the GFP
control (Fig. 7). This result supports our hypothesis that CK2
binding to KSR1 is kinase-independent, offering a potential
mechanism by which both CK2(WT) and CK2(K68M)
maintain ERK phosphorylation and resistance to BRAF and
MEK inhibitors. Specifically, our findings are consistent with a
model whereby CK2 binding enhances the efficiency of KSR1
scaffolding to facilitate ERK activation. Testing of this model
would require identification of the KSR1 binding site on CK2,
which is currently unknown, to enable assessment of whether a
KSR1 binding-deficient mutant of CK2 is now impaired in
conferring resistance to BRAFi and/or MEKi.
ERK Inhibition Avoids CK2-mediated Resistance to RAF-
MEK-ERK Pathway Blockade—Our model predicts that CK2
should not be able to cause resistance in melanoma cells to an
inhibitor downstream of RAF andMEK that acts directly at the
level of ERK. To test this model, we evaluated whether
CK2(WT) or CK2(K68M) could cause resistance to the ERK
inhibitor SCH772984 (1). Consistent with our model, overex-
pression ofCK2(WT), CK2(K68M), orNRAS(Q61K) did not
confer resistance to the ERKi as evidenced by the absence of
either increased GI50 (Fig. 8A) or enhanced clonogenic survival
(Fig. 8B). For evidence that the inhibitor correctly hit its ERK
target, we examined the phosphorylation status of the ERK sub-
strate p90 RSK (Fig. 8C). We (22) and others (1) have shown
recently that decreased phospho-RSK (pRSK) is a more reliable
marker of decreased flux through ERK than is ERK phosphor-
ylation itself, not least because ERK phosphorylation rebounds
quickly, whereas pRSKdoes not. Examination of pRSK in ERKi-
treated cells at the same time point (72 h) as the GI50 analysis
revealed that neither overexpressed CK2 nor mutant NRAS
was able to restore ERK pathway activation in the presence of
ERKi. Thus, although CK2 induces resistance to BRAFi and
MEKi in a kinase-independent manner, even kinase-intact
CK2 does not induce resistance to ERKi, which is an effective
means of impairing the RAF-MEK-ERKpathway in these BRAF
mutant melanoma cells. This finding is similar to other mech-
anisms that cause resistance to RAFi or MEKi in BRAF mutant
melanomas where ERKi sensitivity is retained (1).
Discussion
Although targeted therapies in melanoma have substantially
improved patient outcomes immediately following treatment
in a subset of patients, even responsive patients are confronted
with the inevitable development of resistance months later
(18–21). Understanding the underlying mechanisms of innate
or acquired resistance is key to developing new combination
therapies to overcome tumor unresponsiveness or recurrence.
In the present study, we demonstrate that abnormally elevated
expression of CK2 (CSNK2A1) is sufficient to cause resistance
to each of three small molecule kinase inhibitors of the RAF-
MEK-ERK pathway approved for treatment of melanoma:
vemurafenib, dabrafenib, and trametinib. Furthermore, we
show that this resistance correlates with the rebound/mainte-
nance of ERK activity following pathway inhibition.
Protein kinaseCK2 has been previously shown to affect RAF-
MEK-ERK pathway signaling by various means whose com-
plexity has yet to be fully elucidated. Aside from fine-tuning the
signaling amplitude of the RAF-MEK-ERK pathway, CK2 has
been reported to regulate ERK nuclear translocation and trans-
lation of nuclear targets of ERK, which can also affect the sig-
naling efficiency of the pathway (32). Mechanistically, CK2
kinase activity is needed to phosphorylate Ser-244 and Ser-246
in the nuclear translocation signal of ERK, allowing ERK
binding to Importin7. Although nuclear ERK activation has
not been directly linked to melanoma progression, lack of
cytoplasmic ERK was associated with poor prognosis in pri-
mary cutaneous melanomas (33). Conversely, another study
showed that the proliferation of A375 melanoma cells in
vitro and in vivo was highly sensitive to an inhibitor of ERK
dimerization (34) that is thought to act by decreasing ERK
interactions specifically with its cytoplasmic but not nuclear
substrates (35). The role of CK2 kinase in this process has
not been investigated.
The distinct resistance profiles of CK2 and NRAS(Q61K)
imply different mechanisms of promoting resistance. Specifi-
cally, it is known that secondary NRASmutations that increase
flux through the RAS-MEK-ERK pathway via CRAF activation
can overcome inhibitor potency (24). Such a route of reactiva-
FIGURE7.Bothwild-typeandkinase-inactiveCK2 interactwith theRAF-
MEK-ERK scaffold protein KSR1. Endogenous KSR1 was immunoprecipi-
tated (IP) from A375 cells expressing the GFP control or FLAG-tagged
CK2(WT)or kinase-inactiveCK2(K68M).Whole cell lysates and immunopre-
cipitates were then blotted for the presence of FLAG-CK2 and reprobed for
KSR1 to ensure that equal amounts of KSR1 were immunoprecipitated. *IgG
bands are from immunoprecipitation step. GFP served as a negative control
to rule out nonspecific co-immunoprecipitation of the ectopic CK2 proteins
(n 2).
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tion could easily be blocked byMEK inhibition. Consistentwith
this idea, NRAS(Q61K) did not confer resistance toMEK inhib-
itor trametinib. However, the fact that CK2-mediated resis-
tance is MEK inhibitor-inert suggests two possible mecha-
nisms. The first entails some unknown bypass that leads to
sustained ERK phosphorylation. This is somewhat unlikely
because MEK is still the only known direct activator of ERK.
The second involves steric hindrance provided by CK2 that
prevents anMEK inhibitor frombinding to its target effectively.
Such a mechanism can be provided by a scaffolding function of
CK2 as discussed below.
Intriguingly, we found that wild-type CK2 drastically
reduced expression of the DUSP6, whereas CK2 silencing ele-
vated endogenous DUSP6 protein levels. DUSP6 is a key ERK-
specific phosphatase that negatively regulates the RAF-MEK-
ERK pathway (27). Indeed, DUSP6 has been previously
reported to interact with and be phosphorylated by CK2 (28).
We further show here that CK2-facilitated proteasomal deg-
radation accounts for the decreased abundance of DUSP6 pro-
tein. In light of our results, it would be interesting to know
whether DUSP6 expression could serve as a biomarker of CK2
inhibition.
Much to our initial surprise, we determined, using a kinase-
inactive mutant of CK2, that CK2 kinase activity is not
required for either CK2-mediated inhibitor resistance or sus-
tained ERK phosphorylation in the context of these BRAF
mutant melanoma cells. This was unexpected because CK2 is
well known as a constitutively active kinase that has hundreds
of endogenous substrates, and its kinase activity has largely
been assumed to be responsible for its pleiotropic effects (2–4).
However, the whole-kinome screen by which we identified
CK2 as a potential resistance mechanism capable of inducing
at least a 5-fold increase in resistance to ERK inhibitor was not
performed by inhibition of the catalytic activity of the CK2
kinase but rather by siRNA-mediated depletion of expression of
the entire protein (22). Therefore, this screen would capture
effects induced by loss of protein binding or scaffolding func-
tions as well as by loss of catalytic activities of the depleted
kinases.
Our data suggest that the above resistance phenotypes are
the result of CK2-mediated protein-protein interactions
rather than CK2 kinase activity. Consistent with this notion,
we reported previously that all subunits of CK2 bind to the
RAF-MEK-ERK pathway scaffolding protein KSR1 (31) and
that binding of the CK2 subunit in particular to KSR1 is crit-
ical for maximal activation of the pathway (31). However, we
had not tested whether the kinase activity of CK2 was
required. Because we have now found that kinase deficiency
does not impair CK2 binding to KSR1, we speculate that the
catalytic activity-independent binding of CK2 to KSR1 helps
to promote formation of the KSR1 scaffold complex and to
maintain the integrity and function of the RAF-MEK-ERK
pathway, enabling the sustained ERK phosphorylation
observed in the presence of overexpressedCK2 evenwhen the
pathway is inhibited at the level of RAF or MEK. This hypoth-
esis could be tested in the future once the region of CK2 that
mediates KSR1 binding has been identified as that would allow
interrogation of the ability of KSR1 binding-deficient mutants
of CK2 to confer resistance to pathway inhibitors. Of note,
overexpressed CK2 exists pretreatment. It is also possible that
FIGURE 8. ERK inhibitor SCH772984 is insensitive to overexpression of either CK2(WT) or CK2(K68M).A, the GI50 for ERKi SCH772984 is unchanged by
overexpressionofCK2orbymutantNRAS.GI50 curvesweregeneratedafter 72hof ERKi treatment. Results arepresentedasmeansS.E. (n3).B, clonogenic
survival in the presence of ERKi is not enhanced by overexpressed CK2 or mutant NRAS. Shown are the percentages of colonies formed by A375 cells
expressing GFP, CK2, or NRAS(Q61K) and treated with ERKi (100 nM) normalized to DMSO vehicle control. Results are presented as means S.E. (n 3). n.s.,
non-significant comparedwithGFP.C, ERKi treatment shutsdownERKpathway signalingas indicatedby loss of phosphorylatedERK substratepRSK.A375 cells
as in A and Bwere treated for 24, 48, or 72 h with 100 nM SCH772984. Error bars represent S.E. tERK, total ERK; tRSK, total RSK.
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the trametinib binding site on efficiently scaffolded MEK may
be sterically hindered compared with that of freeMEK, thereby
reducing the effectiveness ofMEK inhibitors. It would also be of
great interest to determine whether the onset of BRAFi/MEKi
resistance in melanoma patients is associated with increased
levels of CK2.
The importance of CK2 protein-protein interactions versus
catalytic kinase activity may differ greatly depending on con-
text. A recent study examined the effects of a CK2-selective
kinase inhibitor, CX-4945, on the viability of BRAFmutant thy-
roid cancer cell lines and found synergism of CX-4945 with
both the BRAFi vemurafenib and the MEKi selumetinib (36),
suggesting that the kinase activity of CK2 was important for
the response to BRAFi/MEKi in this tumor type. Surprisingly,
when they compared the combination of vemurafenib with
CX-4945 or with siRNA directed against CK2 in a patient-
derived BRAF mutant melanoma cell line, they found an addi-
tive effect of each on cell death (36). The equivalent effects on
vemurafenib responses of kinase-intact and kinase-inactive
CK2 that we observed argue that the kinase activity is not
important in the vemurafenib response of BRAF mutant mela-
noma, but it is certainly possible that other genetic differences
may also affect the relative roles of catalytic activity versus pro-
tein-protein interactions. Our study differs fromwork by Borgo
et al. (16), who found a kinase-dependent role of CK2 in ima-
tinib-resistant chronic myeloid leukemia. These differences
may reflect the divergent genetic and epigenetic contexts of
BCR-ABL mutant chronic myeloid leukemia versus BRAF
mutant melanomas. For example, in our model system,
BRAF(V600E) is the driver mutation, and CK2 is an integral
part of the KSR1 scaffolding complex that maximizes signaling
efficiency through the RAF-MEK-ERK pathway. In contrast, in
chronic myeloid leukemia, BCR-ABL is the driver mutation,
and CK2 activity has been shown to be directly regulated by
BCR-ABL (37). Therefore, CK2 can play distinct roles in dif-
ferent tumor contexts. It is also interesting that, although our
original siRNA screen identified CK2 as a mediator of resis-
tance to ERKi in KRAS mutant pancreatic ductal adenocarci-
noma cells (22), CK2 did not mediate resistance to ERKi in
BRAF mutant melanoma cells. We believe that this is also due
to tumor heterogeneity. Indeed,whenweperformed our siRNA
screen in two different pancreatic ductal adenocarcinoma cell
lines, we found that there was little overlap of the hits; CK2
was identified as a hit in CFPAC-1 but not in SW1990 cells.We
were unable to determine the specific basis for such disparate
results, but they certainly highlight the tremendous heteroge-
neity among tumor cell lines, even among those derived from
the same cancer type (e.g. pancreatic ductal adenocarcinoma),
let alone different cancer types (e.g. pancreatic ductal adenocar-
cinoma versus melanoma). Clearly, much remains to be eluci-
dated about the role of CK2 in responses to inhibitors of the
RAF-MEK-ERKpathway, a role that is likely to be as complex as
its hundreds of substrates and numerous biological activities
portend.
In summary, our results identify a role for CK2 in promot-
ing resistance to BRAF and MEK but not ERK inhibitors in
BRAF mutant melanoma. We also demonstrate, for the first
time to our knowledge, a kinase-independent function of CK2
in modulating cellular signaling. These findings represent a
novel mode of innate resistance to RAF-MEK-targeted therapy
in BRAFmutant melanoma, whichmay not be easily addressed
by inhibition of the dysregulatedCK2 kinase. Perhaps ongoing
efforts to developKSR inhibitorsmay achieve success in part via
interference with CK2.
Experimental Procedures
Cell Culture and Reagents—A375, A2058, Sbc12A,Malme-3,
and 293T cell lines were grown in DMEM-H supplemented
with 10% FBS (HyCloneTM, Thermo Scientific) and 1% genta-
mycin/kanamycin (Tissue Culture Facility, Lineberger Com-
prehensive Cancer Center, University of North Carolina at
Chapel Hill). SK-MEL-28 and RPMI-7951 were grown in min-
imum Eagle’s medium  (Gibco) supplemented with 10% FBS
and 1% gentamycin/kanamycin. Primary neonatal human epi-
dermal melanocytes from lightly pigmented, moderately pig-
mented, and darkly pigmented donors were generously pro-
vided by Dr. Guang Hu (National Institute of Environmental
Health Sciences, Research Triangle Park) and were grown in
Medium 245 supplemented with human melanocyte growth
supplement (a kind gift fromDr. GuangHu). The BRAFi vemu-
rafenib (PLX4032) was a generous gift from Gideon Bollag
(Plexxikon). The BRAFi dabrafenib (GSK2118436) and MEKi
trametinib (GSK1120212) were purchased from Selleckchem.
The ERKi SCH772984 was a generous gift from Ahmed Sama-
tar (Merck).MG132was purchased fromCalbiochem (474790).
Plasmid Constructs and Gateway Cloning—The CK2
expression construct, pDONR223-CSNK2A1 (HumanORFeome
v5.1), was purchased from University of North Carolina’s Tis-
sue Culture Facility. pHAGE-FLAG (N-terminal tag) empty
vector was a generous gift from BenMajor, University of North
Carolina at Chapel Hill. Both CK2 and NRAS(Q61K) were
cloned into the pHAGE-FLAGvector byGateway cloning using
LR Enzyme ClonaseMix (Invitrogen) according to themanufa-
cturer’s protocol. A set of five shRNAs targeting CK2
(CSNK2A1) in pLKO.1 vector was purchased from the Lenti-
shRNA Core Facility at University of North Carolina at Chapel
Hill. Target sequences are indicated in Table 1.
Lentivirus Production and Infection—To produce lentivirus,
293T cells were transfected with pHAGE vector-based GFP,
CK2, or NRAS(Q61K) in combination with psPAX2 and
pMD2.G at a ratio of 4:3:1. After overnight transfection, the
culture medium was changed to DMEM-H supplemented
with 20% FBS. Thirty-six hours later, viral supernatants were
harvested and filtered through a sterile 0.45-m filter to
remove cell debris. Cleared supernatants were aliquoted and
frozen at80 °C until use. Cells were infected with 500 l of
virus in 5 g/ml Polybrene (Millipore) overnight. Selection
TABLE 1
Target sequences
TRC, The RNAi Consortium.
shRNA TRC clone ID Target sequence
1 TRCN0000000606 5-GCTGCATTTAGGTGGAGACTT-3
2 TRCN0000000607 5-CGTAAACAACACAGACTTCAA-3
3 TRCN0000000608 5-CAAGAATATAATGTCCGAGTT-3
4 TRCN0000000609 5-AGAATTTGAGAGGAGGTCCCA-3
5 TRCN0000000610 5-CCAAGAATATAATGTCCGAGT-3
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of transduced cells in puromycin (1 or 2 g/ml for A375 or
SK-MEL-28 cells, respectively) was complete at 48 h after
infection.
Western Blotting—Cells werewashed twicewith ice-cold PBS
and lysed in radioimmune precipitation assay buffer (150 mM
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris, pH 8.0) containing 1 protease inhibitors
(BaculoGoldTM protease inhibitor mixture, BD Biosciences,
51-21426Z) and 1 phosphatase inhibitors (HaltTM phospha-
tase inhibitor mixture, Thermo Scientific, 78420). Lysates were
depleted of cell debris by centrifugation at maximum speed
(4 °C, 10 min), and then proteins were quantified by Bradford
assay (DCTM Protein Assay, Bio-Rad), normalized, reduced,
denatured at 95 °C for 5 min, and resolved by SDS gel electro-
phoresis. Proteins were transferred to PDVF membranes (Mil-
lipore, IPFL00010) and probed with primary antibodies recog-
nizing pERK1/2(Thr-202/Tyr-204) (Cell SignalingTechnology,
4370), ERK1/2 (Cell Signaling Technology, 9102), phospho-
MEK1/2(Ser-217/221) (Cell Signaling Technology, 9154),
pRSK(Thr-259/Ser-263) (Cell Signaling Technology, 9344),
DUSP6 (Abcam, ab54940), -actin (Sigma, A5316), CK2
(Santa Cruz Biotechnology, sc-373894), FLAG tag (Sigma,
F3165; Novus, NBP1-06712SS), or GFP (Roche Applied Sci-
ence, 11814460001). A rabbit antibody to the phosphorylated
CK2 substrate EEF1D was a generous gift from David W.
Litchfield (Western University). A rabbit-anti KSR1 antibody
(home-made, Morrison laboratory) was used to detect KSR1
following immunoprecipitation. After incubation with the
appropriate secondary anti-mouse (GE Healthcare, NA931V)
or anti-rabbit (GE Healthcare, NA934V) antibody, proteins
were detected by chemiluminescence (Thermo Scientific,
34075). Blotswere developed by exposure to x-ray filmor by the
ChemiDocTM MP Imaging System (Bio-Rad) for quantifica-
tion. Film was scanned, and densitometry analysis was per-
formed with ImageJ 1.45s.
Pharmacologic GI50 Assay—Growth inhibition assays were
performed as described previously (24, 38) with minor modifi-
cations. Cultured cells were seeded into 96-well plates (2,000
cells/well). Sixteen hours after seeding (baseline), serial dilu-
tions of inhibitors were prepared in DMSO and added to cells,
yielding final drug concentrations ranging from 1 nM to 10
M for vemurafenib, dabrafenib, and SCH772984 and 0.1 nM
to 1 M for trametinib with the final volume of DMSO not
exceeding 1%. Cells were incubated for 72 h following addi-
tion of drug. To measure cell proliferation, 5 mg/ml 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Sigma-Aldrich, M5655) was added 1:10 into wells and incu-
bated at 37 °C for 4 h. Formazan products were solubilized
using acidified isopropanol (0.04 N HCl in isopropanol), and
absorbance was measured at 562 nm with a background sub-
traction at 650 nm. Percent cell growth under each condition
was calculated as follows: Cell growth (%) 100 (T  T0)/
(C  T0) where T0 is absorbance at baseline, T is absorbance
of drug-treated wells at 72 h, and C is absorbance of DMSO-
treated wells at 72 h. A minimum of three replicates was
performed for each cell line and drug combination. Data
from growth inhibition assays were modeled using a non-
linear regression curve fit with a sigmoidal dose response
(GraphPad Prism, v5.0c). The resulting curves were dis-
played and GI50 values were also generated using GraphPad
Prism.
Clonogenic Assay—Clonogenic assays were performed as
described previously (39) with slight modifications. Briefly,
cells were plated in duplicate wells at 100 cells/well in 6-well
plates and allowed to adhere for 3 h at 37 °C after which culture
medium was carefully removed and replaced with medium
containing either DMSO vehicle control or inhibitor. Two
weeks following drug treatment, cells were washed once with
PBS and then fixed and stained with crystal violet/parafor-
maldehyde for 30 min at room temperature. The stain was
decanted, and plates were carefully rinsed with distilled
water until background staining of the wells was minimized.
Finally, plates were air-dried, and colonies were counted
manually using a cell counter.
Site-directed Mutagenesis—Site-directed mutagenesis of
CK2 was performed using a QuikChange II XL site-directed
mutagenesis kit (Agilent). Forward primer 5-GCCATCAAC-
ATCACAAATAATGAAAAAGTTGTTGTTATGATTCTC-
AAGCCAG-3 and reverse primer 5-CTGGCTTGAGAAT-
CATAACAACAACTTTTTCATTATTTGTGATGTTGAT-
GGC-3 were used to introduce a catalytic site mutation (K68M)
into pDONR223-CSNK2A1 with bold nucleotides showing the
site of mutagenesis. Reaction conditions strictly followed the
manufacturer’s protocol.
RNA Isolation, Reverse Transcription, and Real Time PCR—
Total RNA was isolated from cells using the Thermo RNA kit
(Thermo Scientific), and then 0.5 g of total RNA was reverse
transcribed to generate cDNA using the iScriptTM cDNA syn-
thesis kit (Bio-Rad) according to the manufacturer’s instruc-
tions. Real time PCR was performed using the SsoFastTM
EvaGreen Supermix (Bio-Rad) on the Bio-Rad CFX-96 Real-
Time PCR System.-Actin was used for normalization. DUSP6
was amplified using forward primer 5-CGACTGGAACG-
AGAATACGG-3 and reverse primer 5-TTGGAACT-
TACTGAAGCCACCT-3.
Co-immunoprecipitation—Co-immunoprecipitation assays
were performed as described previously (31). In brief, two
10-cm dishes of A375 cells were washed twice with cold PBS
and lysed in 1% Nonidet P-40 buffer (20 mM Tris, pH 8.0, 137
mM NaCl, 10% glycerol, 1% Nonidet P-40 alternative, 0.15
unit/ml aprotinin, 1mM phenylmethylsulfonyl fluoride, 0.5mM
sodium vanadate, 20 M leupeptin) using 600 l of lysis buffer/
10-cm dish. The lysates were clarified by centrifugation,
and equivalent amounts of protein lysate were incubated
with a mouse anti-human KSR1 antibody (Sigma-Aldrich,
WH0008844M1) and protein G-Sepharose beads for 3 h at
4 °C. Immunoprecipitated complexes were collected by centrif-
ugation, washed extensively with 1% Nonidet P-40 buffer, and
then examined by immunoblotting analysis.
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